- Conditions
- Sickle Cell Disease, Vaso-occlusive Pain Episode
- Interventions
- L-arginine, L-arginine Loading Dose, Placebo
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,858
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alcoholic Hepatitis
- Interventions
- DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC)
- Drug
- Lead sponsor
- Durect
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 33 more
- Conditions
- Lupus Nephritis
- Interventions
- BIIB023, Placebo, mycophenolate mofetil, oral corticosteroids
- Biological · Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 9
- States / cities
- Torrance, California • Orlando, Florida • Boston, Massachusetts + 6 more
- Conditions
- Breast Cancer
- Interventions
- ramucirumab (IMC-1121B), docetaxel, Placebo
- Biological · Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 52 more
- Conditions
- Diabetes type1
- Interventions
- AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
- Biological · Drug
- Lead sponsor
- Precigen Actobio T1D, LLC
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Placebo, GM-CSF
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Atlanta, Georgia • Ann Arbor, Michigan
- Conditions
- Type 2 Diabetes
- Interventions
- XOMA 052, Placebo
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Escondido, California • Miami Gardens, Florida • Omaha, Nebraska + 1 more
- Conditions
- Anemia, Iron Deficiency, Delivery Complication
- Interventions
- Ferrous sulfate, Iron dextran
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Coronary Heart Disease, Graft Occlusion, Vascular
- Interventions
- Placebo, RO4905417
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 21 more
- Conditions
- Malignant Melanoma
- Interventions
- Intismeran autogene, Pembrolizumab, Placebo
- Biological · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Springdale, Arkansas • San Francisco, California • Hackensack, New Jersey + 2 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
- Interventions
- Inclacumab, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
- Conditions
- Bariatric Surgical Pain
- Interventions
- Lidocaine, Placebo
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Frailty
- Interventions
- Mesenchymal Stem Cells (MSCs)
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 20 more
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
- Interventions
- JK07, Placebo
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 51
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more
- Conditions
- Diabetes, Peripheral Neuropathy, Pain
- Interventions
- lidocaine, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Pimasertib, Gemcitabine, Placebo
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Stroke, Cerebral Ischemia, Brain Infarction
- Interventions
- Ancrod (Viprinex), Placebo
- Drug
- Lead sponsor
- Neurobiological Technologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Loma Linda, California + 48 more
- Conditions
- Alpha1-antitrypsin Deficiency, Healthy Volunteers
- Interventions
- Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Parkinsons Disease
- Interventions
- Prasinezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- elezanumab, placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Berkeley, California • Carlsbad, California + 24 more
- Conditions
- Myocarditis Acute, Cancer
- Interventions
- Abatacept plus, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo
- Biological
- Lead sponsor
- aTyr Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more
- Conditions
- Stomach Neoplasms
- Interventions
- Pembrolizumab, Cisplatin, 5-fluorouracil, oxaliplatin, capecitabine, Placebo for Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orange, California • Miami, Florida + 7 more